Company: University Hospital Essen
Job title: Group Leader, Institute for Transfusion Medicine
Bernd Giebel received his PhD 1996 at the University zu Köln in Developmental Biology. From 1999-2008 he worked at the Heinrich-Heine-University of Düsseldorf on human hematopoietic stem and progenitor cells and set up his own group. Continuing his stem cell research, in 2008 BG moved to the University Hospital Essen. In 2009, as a 2nd topic his group started to work with EVs, setting a focus on mesenchymal stem/stromal cell-derived EVs (MSC-EVs). Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics. He is the president of the German Society of Extracellular Vesicles (GSEV), co-chairing the exosome working of the group of the International Society of Gene and Cell Therapy (ISCT) and part of the scientific advisory board of two SME companies, Innovex Therapeutics and EVOX.
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Potential Modulators of the Immune System in Many Diseases 11:00 am
According to controversial reports in the MSC field, especially since a phase III clinical trial failed to show clinical efficacy in MSC treated GvHD patients, we consider that MSC-EV preparations do not warrant therapeutic successes in general At the experimental level we confirmed EVs prepared from MSCs of different donors can significantly vary in their…Read more
day: Day Two